Skip to main content
SpringerLink
Log in

Tropisetron

A Review of the Clinical Experience

  • Published:
Drugs Aims and scope Submit manuscript

Summary

This review describes clinical experience with tropisetron, a new 5-hydroxytryptamine type 3 (serotonin3)-receptor antagonist, which was found to possess antiemetic properties in animal studies and pilot studies in chemotherapy-treated patients. Tropisetron 5mg once daily is an effective and well tolerated antiemetic treatment for chemotherapy-induced emesis. Tropisetron can be administered without special precautions to all patients who undergo aggressive chemotherapy, and remains effective during multiple chemotherapy courses. The efficacy of tropisetron compares well with that of the best available complicated antiemetic cocktails, but tropisetron is better tolerated. The simple dosage schedule of either 1 injection or 1 capsule per day makes tropisetron ideal for both inpatient and outpatient treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacological Sciences 9: 334–341, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bleiberg H, Van Belle S, Paridaens R, De Wasch G, Dirix LY, et al. Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment. Drugs 43(Suppl. 3): 27–32, 1992

    Article  PubMed  Google Scholar 

  • Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. European Journal of Cancer 27: 561–565, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bruntsch U, Drechsler S, Hiller E, Eiermann W, Tulusan AH, et al. Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy. Drugs 43(Suppl. 3): 23–26, 1992

    Article  PubMed  Google Scholar 

  • Dogliotti L, Antonacci RA, Pazè E, Ortega C, Berruti A, et al. Three years’ experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Drugs 43(Suppl. 3): 6–10, 1992

    Article  PubMed  Google Scholar 

  • Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine 305: 905–909, 1981

    Article  PubMed  CAS  Google Scholar 

  • Homesley HD, Gainey JM, Jobson VW, Welander CE, Muss HB, et al. Double-blind placebo-controlled study of metoclopramide. New England Journal of Medicine 307: 205, 1982

    Article  Google Scholar 

  • Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 60: 2816–2822, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of Clinical Oncology 3: 1379–1384, 1985b

    PubMed  CAS  Google Scholar 

  • Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide dexamethasone, and diphenhydramine. Cancer 55: 527–534, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, et al. Extrapyramidal reactions with high-dose metclopramide. New England Journal of Medicine 309: 433–434, 1983

    PubMed  CAS  Google Scholar 

  • Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1: 1198, 1987

    Article  PubMed  CAS  Google Scholar 

  • Marty M, Pouillart P, Scholl S, Droz JP, Azab M, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. New England Journal of Medicine 322: 816–820, 1990

    Article  PubMed  CAS  Google Scholar 

  • Meyer BR, O’Mara V, Reidenberg MM. A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. Journal of Clinical Oncology 5: 1994–1997, 1987

    PubMed  CAS  Google Scholar 

  • Seinen H, Zonnenberg BA, Tjia P, Neijt JP. The effect of three dose levels of ICS 205-930 (a selective 5-HT3 antagonist) on cisplatin-induced nausea and vomiting. European Journal of Cancer and Clinical Oncology 25: 1333–1335, 1989

    Article  CAS  Google Scholar 

  • Sorbe B, Berglind A-M. Tropisetron, a new 5-HT3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea. Drugs 43(Suppl. 3): 33–39, 1992

    Article  PubMed  Google Scholar 

  • Strum SB, McDermed JE, Opfell RW, Riech LP. Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. Journal of the American Medical Association 247: 2683–2686, 1982

    Article  PubMed  CAS  Google Scholar 

  • Tyson LB, Gralla RJ, Kris MG, Clark RA. Phase I antiemetic study of the serotonin antagonist ICS 295-930. Proceedings of ASCO Vol. 8: 331, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Research, Sandoz Pharma, CH-4002, Basel, Switzerland

    Karel M. de Bruijn

Authors
  1. Karel M. de Bruijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Bruijn, K.M. Tropisetron. Drugs 43 (Suppl 3), 11–22 (1992). https://doi.org/10.2165/00003495-199200433-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200433-00005

Keywords

Search

Navigation